Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

41.44USD
29 Sep 2016
Change (% chg)

-- (--)
Prev Close
$41.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,869,983
52-wk High
$46.38
52-wk Low
$36.00

ABT

Chart for ABT

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $60,916.61
Shares Outstanding(Mil.): 1,469.99
Dividend: 0.26
Yield (%): 2.51

Financials

  ABT Industry Sector
P/E (TTM): 31.81 37.66 37.54
EPS (TTM): 1.30 -- --
ROI: 5.91 14.54 13.98
ROE: 8.91 15.32 14.88

BRIEF-Terumo Corp looks to purchase portion of Abbott Laboratories' medical device business - Nikkei

* Terumo Corp is looking to purchase a portion of Abbott Laboratories' medical device business - Nikkei

Sep 29 2016

BRIEF-Abbott receives FDA approval for the FreeStyle Libre Pro System

* Abbott receives FDA approval for the FreeStyle Libre Pro System, a revolutionary diabetes sensing technology for healthcare professionals to use with their patients Source text for Eikon: Further company coverage:

Sep 28 2016

BRIEF-Abbott says malnutrition adds $15.5 bln annually to direct U.S. medical costs

* Research Shows Malnutrition Associated With Disease Increases Medical Spending By More Than $1 Billion Yearly In California, New York, Texas,Florida

Sep 21 2016

BRIEF-Moody's says expectations for Abbott's ratings unchanged

* Moody's says expectations for Abbott's ratings unchanged following news of medical optics sale Source text for Eikon: Further company coverage:

Sep 19 2016

Abbott to sell its eye care business to J&J for about $4.33 billion

Abbott Laboratories said it would sell its eye care business to Johnson & Johnson for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.

Sep 16 2016

UPDATE 3-Abbott to sell its eye care business to J&J for about $4.33 bln

Sept 16 Abbott Laboratories said it would sell its eye care business to Johnson & Johnson for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.

Sep 16 2016

BRIEF-Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 bln

* Net impact of this transaction is not expected to impact Abbott's overall targeted ongoing earnings per share in 2017.

Sep 16 2016

Abbott in talks to sell its eye-surgery business to J&J - WSJ

Sept 16 Abbott Laboratories is in talks to sell its eye-surgery business to Johnson & Johnson, the Wall Street Journal reported, citing sources familiar with the matter.

Sep 16 2016

Abbott, Alere agree to mediate merger dispute

Medical device maker Abbott Laboratories and Alere Inc agreed on Thursday to work with a mediator to settle their dispute over Abbott's role in obtaining U.S. antitrust clearance for its $5.8 billion takeover of the diagnostics company, but Alere voiced concern about the speed of the process.

Sep 08 2016

Abbott, Alere agree to mediate merger dispute

Medical device maker Abbott Laboratories and Alere Inc agreed on Thursday to work with a mediator to settle their dispute over Abbott's role in obtaining U.S. antitrust clearance for its $5.8 billion takeover of the diagnostics company, but Alere voiced concern about the speed of the process.

Sep 08 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $117.27 -2.12
Pfizer Inc. (PFE.N) $33.32 -0.67
Novartis AG (NOVN.S) CHF75.90 -1.35
Merck & Co., Inc. (MRK.N) $61.91 -1.39
Sanofi SA (SASY.PA) €67.27 -0.76
AstraZeneca plc (AZN.L) 4,970.50p -55.50
GlaxoSmithKline plc (GSK.L) 1,635.39p -12.50
Eli Lilly and Co (LLY.N) $79.74 -0.97
Amgen, Inc. (AMGN.OQ) $165.45 --
Boston Scientific Corporation (BSX.N) $23.30 -0.45

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.